Ptc Therapeutics (PTCT) Gross Margin (2017 - 2025)
Historic Gross Margin for Ptc Therapeutics (PTCT) over the last 10 years, with Q3 2025 value amounting to 92.52%.
- Ptc Therapeutics' Gross Margin fell 19700.0% to 92.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 96.83%, marking a year-over-year increase of 66700.0%. This contributed to the annual value of 92.89% for FY2024, which is 1300.0% down from last year.
- Latest data reveals that Ptc Therapeutics reported Gross Margin of 92.52% as of Q3 2025, which was down 19700.0% from 93.62% recorded in Q2 2025.
- Ptc Therapeutics' 5-year Gross Margin high stood at 98.91% for Q1 2025, and its period low was 90.52% during Q4 2023.
- Over the past 5 years, Ptc Therapeutics' median Gross Margin value was 93.6% (recorded in 2023), while the average stood at 93.79%.
- In the last 5 years, Ptc Therapeutics' Gross Margin plummeted by -29800bps in 2023 and then skyrocketed by 59200bps in 2025.
- Quarter analysis of 5 years shows Ptc Therapeutics' Gross Margin stood at 94.36% in 2021, then decreased by -1bps to 93.49% in 2022, then fell by -3bps to 90.52% in 2023, then rose by 2bps to 92.36% in 2024, then rose by 0bps to 92.52% in 2025.
- Its last three reported values are 92.52% in Q3 2025, 93.62% for Q2 2025, and 98.91% during Q1 2025.